We hope to see you at this year's BIO International Convention June 6th through 9th in San Francisco. The BIO International Convention attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The event covers a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
To help you better prepare for the often complex partnering process ShareVault and BIO, along with LES, have teamed up to present a web panel discussion intitled, "The Nuts & Bolts of Due Diligence in BioPharma Partnering." This live and lively discussion will focus on best practices for due diligence for forming productive biopharma partnerships.
During the panel, biotech licensing and pharmaceutical business development consultant Linda Pullan will be joined by six panelists who are experts in the field of biopharma partnering due diligence.
The panel includes two due diligence experts from global pharmaceutical companies, the Chief Operating Officer of a biopharma with cancer drugs in development in partnership with a global pharmaceutical company, an attorney with expertise in biotechnology licensing, and two consultants with expertise in corporate and business development and the issues that arise during due diligence and afterward, if due diligence hasn't been done well.
The panelists will discuss the most important aspects to consider during the due diligence process leading up to a successful partnership. Among the topics covered in the discussion are:
- The importance of IP due diligence
- What large pharma expects when entering due diligence with a biopharma company
- Best ways to present and stage information that is disclosed to a potential partner
- Common mistakes and how to avoid them
- How to recognize potential problems and address them early in the process
- The best practices for the best long-term partnerships
- And more...
If you are seeking to partner with another biopharmaceutical company, or desire to out- or in-license a drug or other asset, you'll want to hear these perspectives.
About the Panelists:
Linda Pullan, PhD
Linda offers biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a PhD in Biochemistry, a BS in Chemistry, and more than twenty years of drug industry experience.
James A. McCarthy, CLP, MBA
Corporate and Business Development, Alliance Management, CorpDev Ventures
Jim has thirty years of life sciences professional experiences. His background includes a twenty-five year career with Bristol-Myers Squibb and Eli Lilly & Company and over fifteen years in international corporate business development and licensing roles. These efforts included projects and deals in over 30 countries with over 80 completed agreements across a range of transactions valued in excess of $900 million. He holds an MBA from Indiana University, a B.S. in Physical Therapy from SUNY Upstate Medical Center, and is a recipient of the Certified Licensing Professional (CLP) designation.
Natalie Mirutenko, PhD
Transaction and Due Diligence Senior Director for the Center of External Innovation at Takeda
Natalie is an accomplished biopharmaceutical Business Development professional with a strong track record of results oriented achievements in technology, company, and product licensing and acquisition. She has over 35 years of diversified biopharmaceutical experience, with scientific, financial, strategic, and business perspective. Her extensive experience also includes leading scientific assessment, due diligence and deal valuation, negotiation and execution with a genuine passion for seeking out new business opportunities and creative deal structures. She is an Immunologist by training and is an accomplished business executive with 35 years of business development, licensing and drug development experience.
David L. Snitman, PhD
Partner, DL Snitman Inc and Former COO, Array BioPharma
David is a partner in a biotech business development-consulting agency, DL Snitman Inc. He is a Cofounder of Array BioPharma and had served as Chief Operating Officer and Vice President of Business Development from 1998 to 2015. During his tenure at Array he lead over a dozen partnering deals, providing more then $600M in non-dilutive capital. He served as a member of the Board of Directors from May 1998 to October 2012. Prior to forming Array, David held various positions with Amgen Inc. since 1981, including Associate Director, New Products and Technology and Manager of Amgen's Boulder research facility. David received a BS in chemistry from Northeastern University and obtained a PhD in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology.
Patrick Gattari, JD
Partner, McDonnell Boehnen Hulbert & Berghoff
Patrick's practice focuses on patent prosecution and technology licensing, with emphasis in biotechnology, pharmaceuticals, diagnostics, and medical devices. His 20-plus years of practice has emphasized patent portfolio management and the licensing, acquisition, and sale of intellectual property. Prior to joining MBHB, Patrick was patent counsel at Dade Behring, Inc. (now Siemens Healthcare Diagnostics). Early in his career, he worked for Abbott Laboratories in a variety of positions focusing on the development and production of pharmaceuticals and diagnostic products.
Ann-Marie Costelloe, AFBPS, Chartered Organization Psychologist | Executive Consultant, Somerville Partners
With over 20 years of organizational development consulting with organizations, teams and individuals, Ann-Marie directly contributes to financial success by customizing solutions to assist leaders increase employee engagement and contributions, align strategy and tactics, and elevate performance across the business. Ann-Marie also provides due diligence assessments of target management teams for VC and PE firms.
William Gangi, MS, MBA | Director, Due Diligence Program Manager - Corporate Development, Shire
William currently serves as a Director, Due Diligence Program Manager within the Corporate Development department at Shire. He has 20 years of drug development, commercialization and strategic operations experience within the biopharmaceutical industry. He received a BS and MS in Biology from St. John's University and a MBA from The Kellogg School of Management at Northwestern University.